Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 22, 2021 06:30 ET | Source: Affimed N.V.

Affimed to Report First Quarter 2021 Financial Results & Corporate Update July 1, 2021

HEIDELBERG, Germany, June 22, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical stage immuno-oncology company committed to giving patients back their innate ability to fight cancer,...
June 16, 2021 07:04 ET | Source: Affimed N.V.

Affimed Announces Appointment of Uta Kemmerich-Keil to its Supervisory Board

HEIDELBERG, Germany, June 16, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer,...
May 26, 2021 06:30 ET | Source: Affimed N.V.

Affimed to Present at the Jefferies Virtual Healthcare Conference 2021

Heidelberg, Germany, May 26, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that...
May 20, 2021 16:30 ET | Source: Affimed N.V.

Affimed Announces Virtual Annual General Meeting of Shareholders

Heidelberg, Germany, May 20, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that...
May 13, 2021 16:01 ET | Source: Affimed N.V.

Affimed Announces Publication of Preclinical Data in Clinical Cancer Research Supporting Therapeutic Potential of AFM13 in Combination with Natural Killer Cells

AFM13 in combination with natural killer (NK) cells demonstrated improved tumor recognition and enhanced tumor cell killing in vitro and in vivo.Preclinical data from this publication...
April 15, 2021 06:30 ET | Source: Affimed N.V.

Affimed Reports 2020 Financial Results and Highlights Recent Operational Progress

AFM13 monotherapy: Reported positive data from the preplanned interim analysis for the registration-directed trial in PTCLAFM13 combination with NK cells: Announced 100% objective response rate in...
April 12, 2021 06:30 ET | Source: Affimed N.V.

Affimed Highlights the Potential of its Innate Cell Engager AFM24 as EGFR-targeting Therapy for Solid Tumors as Monotherapy and in Combination with Adoptive NK Cell Transfer at AACR Virtual Annual Meeting I

AFM24 induces strong tumor cell killing independent of KRAS mutationsAFM24, in combination with adoptive NK cells, leads to dose-dependent tumor regression Heidelberg, Germany, April 12, 2021 –...
April 09, 2021 05:59 ET | Source: Affimed N.V.

Affimed Announces Presentation at AACR Highlighting Initial Data from Phase 1 Study of Cord Blood-derived Natural Killer Cells Pre-complexed with Innate Cell Engager AFM13

All four patients experienced significant disease reduction, with two complete responses and two partial responses as assessed by the investigator, with an objective response rate of...
April 08, 2021 06:30 ET | Source: Affimed N.V.

Affimed to Report Full Year 2020 Financial Results & Corporate Update on April 15, 2021

Heidelberg, Germany, April 8, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that...
March 31, 2021 06:30 ET | Source: Affimed N.V.

Affimed and NKMax America Announce FDA Clearance of IND Application to Study the Combination of AFM24, an EGFR Targeted Innate Cell Engager, with SNK-01 Natural Killer Cell Therapy in Solid Tumors

Heidelberg, Germany and Santa Ana, Calif., March 31, 2021 - Affimed N.V. (NASDAQ: AFMD), a clinical-stage immuno-oncology company, and NKMax America Inc., a clinical stage biotech company, announced...